Medscape |
FDA Approves Cinqair To Treat Severe Asthma
Pharmacy Practice News The FDA has approved reslizumab (Cinqair, Teva Pharmaceuticals) as an add-on maintenance treatment for patients aged 18 years and older with an eosinophilic phenotype asthma, who have a history of severe exacerbations despite receiving their current … FDA approves reslizumab to treat severe asthma Reslizumab (Cinqair) Approved to Treat Severe Asthma Cinqair Receives FDA Approval As Treatment For Severe Asthma |
View full post on asthma – Google News